1 month Is Pfizer’s Attractive Valuation Enough to Invest in the Stock?Zacks
PFE’s non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
XPFE’s non-COVID drugs and potential contributions from new and newly acquired products have started to drive growth.
X